Zegfrovy has snagged the world’s first Phase III win among its small molecule peers for the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (exon20in) mutations in a front-line setting. (Shutterstock)
Keep up with the top pharma business news of the week. On the go.
